1Senderowicz AM. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologists, 2002, 7: 12-19.
2Zhai S, Senderowicz AM, Sausville EA, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacol, 2002, 36: 905-911.
3Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase(CDK)2 and CDK4 in human breast carcinoma cells. Cancer Res, 1996, 56: 2973-2978.
4Rapella A, Negrioli A, Melillo G, et al. Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. Int J Cancer, 2002, 99: 658-664.
5de Azevedo WF, Canduri F, da Silveira NJF. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun, 2002, 293: 566-571.
7Decker RH, Dai Y, Grant S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells(U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ, 2001, 8: 715-724.
8Pepper C, Thomas A, Hog T, et al. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukemia. Br J Haematol, 2001, 114: 70-77.
9Ma Y, Cress D, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F-1 and repression of Mcl-1. Mol Cancer Ther, 2003, 2: 73-81.
10Mihara M, Shintani S, Nakashiro K, et al. Flavopiridol, a cyclin-dependent kinase(CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells. Oral Oncol, 2003, 39: 49-55.
